ClinicalTrials.gg

Program

BAY 3670549

A development code.

Its studies are mostly in Atrial Fibrillation, led by Bayer.

Furthest: phase 2, since May 13, 20261 company-led study, 1 open or runningNext primary completion: May 16, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer11 open or runningphase 2since May 13, 2026May 13, 2026May 16, 2030phase 2 · NCT07625215

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2026First study: phase 2 study in Atrial FibrillationFirst studyNCT07625215 · 360 planned · United States, Belgium, Bulgaria and more

Ahead

  1. May 16, 2030Primary completion: phase 2 study in Atrial FibrillationNCT07625215

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07625215Atrial Fibrillation · United States, Belgium, Bulgaria and more2RecruitingMay 16, 2030360

How it is read

Names in the registry

  • “BAY 3670549”, 1 entry

Codes read as this program: BAY3670549.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.